Immuron Ltd — Capital/Financing Update 2019

May 23, 2019

==> picture [209 x 63] intentionally omitted <==

Underwritten public offer

Melbourne, Australia, May 24, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, as announced earlier today, the Company has entered into an underwritten public offer of 500,000 American Depositary Shares, or ADSs. Each ADS represents forty (40) ordinary shares of the Company with a public offering price of USD$4.00 per ADS.

The Company intends to issue the securities under its 15% capacity under Listing Rule 7.1.

The offering is expected to close on May 29, 2019, subject to customary closing conditions. The estimated gross proceeds to the Company are expected to be approximately USD$2,000,000 prior to deducting underwriting discounts, commissions and other estimated offering expenses.

Refer to earlier announcements for further details including how to obtain copies of the final prospectus supplement and accompanying prospectus relating to the offering.

-End-